Lexeo reports positive phase 1/2 data for LX2020
Regulatory progress supports accelerated approval pathway Lexeo Therapeutics has reported positive interim results from its ongoing phase 1/2 HEROIC-PKP2 clinical trial evaluating LX2020 in patients with PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM), alongside a regulatory update that may support an accelerated approval pathway. The company said LX2020 was generally well tolerated across 10 participants treated in the […]
